A joint assessment is a structured information for rapid or full/comprehensive HTAs which is the output of joint production in which 2 or more countries and/or organisations work together to prepare shared products or agreed outcomes (Based on definitions from the HTA Network Strategy (page 24) and the EUnetHTA Recommendations (page 6, footnote 8))
Methodological guideline for REA of pharmaceuticals: Clinical endpoints
JA-WP5 EUnetHTA Joint Action (2010-12)
2013 - PDF
This guideline provides a set of recommendations for the selection and assessment of clinical endpoints when completing a Relative Effectiveness Assessment (REA) of pharmaceuticals.
Clinical endpoints are regarded as a means to measure the impact of a treatment on how a patient feels, functions and survives. That impact is usually in the form of improved health status (e.g. survival, cure, remission), but it may also be worsened health status (e.g. adverse reactions, hospitalisations, death). Clinical endpoints can be broadly categorised into three domains: mortality, morbidity and Health Related Quality of Life (HRQoL) measures. The endpoints reported for an assessment should be clearly relevant to the disease, condition or process of interest.
Please find the guideline on clinical endpoints at the bottom of this page.